Impact of a Central-Line Insertion Site Assessment (CLISA) score on localized insertion site infection to prevent central-line-associated bloodstream infection (CLABSI).


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 9 11 2019
medline: 15 12 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

To assess the impact of a newly developed Central-Line Insertion Site Assessment (CLISA) score on the incidence of local inflammation or infection for CLABSI prevention. A pre- and postintervention, quasi-experimental quality improvement study. Adult inpatients with central venous catheters (CVCs) hospitalized in an intensive care unit or oncology ward at a large academic medical center. We evaluated CLISA score impact on insertion site inflammation and infection (CLISA score of 2 or 3) incidence in the baseline period (June 2014-January 2015) and the intervention period (April 2015-October 2017) using interrupted times series and generalized linear mixed-effects multivariable analyses. These were run separately for days-to-line removal from identification of a CLISA score of 2 or 3. CLISA score interrater reliability and photo quiz results were evaluated. Among 6,957 CVCs assessed 40,846 times, percentage of lines with CLISA score of 2 or 3 in the baseline and intervention periods decreased by 78.2% (from 22.0% to 4.7%), with a significant immediate decrease in the time-series analysis (P < .001). According to the multivariable regression, the intervention was associated with lower percentage of lines with a CLISA score of 2 or 3, after adjusting for age, gender, CVC body location, and hospital unit (odds ratio, 0.15; 95% confidence interval, 0.06-0.34; P < .001). According to the multivariate regression, days to removal of lines with CLISA score of 2 or 3 was 3.19 days faster after the intervention (P < .001). Also, line dwell time decreased 37.1% from a mean of 14 days (standard deviation [SD], 10.6) to 8.8 days (SD, 9.0) (P < .001). Device utilization ratios decreased 9% from 0.64 (SD, 0.08) to 0.58 (SD, 0.06) (P = .039). The CLISA score creates a common language for assessing line infection risk and successfully promotes high compliance with best practices in timely line removal.

Identifiants

pubmed: 31699181
pii: S0899823X19002915
doi: 10.1017/ice.2019.291
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-66

Subventions

Organisme : AHRQ HHS
ID : R01 HS024424
Pays : United States

Auteurs

Shruti K Gohil (SK)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.
Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Jennifer Yim (J)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.

Kathleen Quan (K)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.

Maurice Espinoza (M)

University of California, Irvine Health, Orange, California.

Deborah J Thompson (DJ)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.

Allen P Kong (AP)

Department of Surgery, University of California, Irvine School of Medicine, Irvine, California.

Bardia Bahadori (B)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Tom Tjoa (T)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Chris Paiji (C)

Department of Medicine, University of California, Irvine School of Medicine, Irvine, California.

Scott Rudkin (S)

Department of Emergency Medicine, University of California, Irvine School of Medicine, Irvine, California.

Syma Rashid (S)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Suzie S Hong (SS)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Linda Dickey (L)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.

Mohamad N Alsharif (MN)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

William C Wilson (WC)

Department of Anesthesia, University of California, Irvine School of Medicine, Irvine, California.
University of California, Irvine Health, Orange, California.

Alpesh N Amin (AN)

Department of Medicine, University of California, Irvine School of Medicine, Irvine, California.
University of California, Irvine Health, Orange, California.

Justin Chang (J)

Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Usme Khusbu (U)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.

Susan S Huang (SS)

Epidemiology & Infection Prevention Program, University of California, Irvine Health, Orange, California.
Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH